https://en.bioecon.ru/companies/pfizer/Recent content in Pfizer on BioeconHugoen-USThu, 23 Jul 2026 23:05:33 +0700https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/Mon, 01 Jan 0001 00:00:00 +0000https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/Targeted oncology therapies utilizing monoclonal antibodies to deliver highly potent cytotoxic payloads directly to cancer cells, minimizing systemic toxicity.